Business Context and Reporting Period
Company: ANAVEX LIFE SCIENCES CORP.
Filing Type: Form 8-K (Current Report)
Report Date: April 19, 2011 (Earliest event reported)
Sign-off Date: April 26, 2011
Context: The filing reports unregistered sales of equity securities and a significant clinical trial milestone for the company's lead Alzheimer's disease compound, ANAVEX 2-73.
Key Financial Metrics and Capital Structure
- Debt Issuance: Arranged sale of $1,000,000 in convertible debentures.
- Initial Closing: Issued one $250,000 convertible debenture on April 20, 2011.
- Interest Rate: 8% per annum on the principal amount.
- Maturity Date: April 20, 2012, or earlier upon conversion or retirement.
- Transaction Fees: $100,000 paid to the purchaser for arranging the debentures.
- Conversion Terms: Convertible at $3.00 per share into units (1 share + 1 warrant).
- Warrant Terms: Warrants exercisable at $4.00 per share for two years.
- Additional Rights: Investor has a 5-day window to acquire 33,334 shares and 33,334 warrants for $100,000.
Note: The filing does not provide specific revenue, profit, cash flow, or liquidity metrics for the period.
Material Changes and Operational Events
- Clinical Trial Milestone: On April 20, 2011, the company announced that the first healthy human volunteers have been initially dosed in the Phase I clinical trial for ANAVEX 2-73.
- Capital Structure Change: The company has initiated a $1,000,000 financing round via convertible debentures, with the remainder expected to close within one month of the initial issuance.
Guidance, Risks, and Contingencies
- Regulatory Compliance: Securities were issued to a non-U.S. person in an offshore transaction relying on Regulation S and/or Section 4(2) exemptions of the Securities Act of 1933.
- Financial Obligations: The debentures are unsecured obligations carrying an 8% interest rate, creating a fixed cost of capital until maturity or conversion.
- Future Dilution: Conversion of debentures and exercise of warrants will result in the issuance of additional common stock, subject to the specified conversion and exercise prices.
Investor Verification Checklist
- Confirm the closing status of the remaining $750,000 of the convertible debenture offering.
- Verify the progress and safety data from the Phase I clinical trial for ANAVEX 2-73 following the initial dosing.
- Review the impact of the $100,000 transaction fee on the company's immediate cash position.
- Monitor the potential dilution impact based on the $3.00 conversion price and $4.00 warrant exercise price relative to the current market price.